Clinical Trials on Multiple Myeloma of Bone (Diagnosis)

Total 10109 results

National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Isfahan University of Medical Sciences

Completed

Is Analgesic Effect of Low Dose Ketamine-midazolam the Same as Morphine

Closed Multiple Fractures of Upper and Lower Limbs
Vésale Hospital
Janssen-Cilag Ltd.

Completed

Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients

Prevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of Onychomycosis

Belgium
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Jacob Laubach, MD
Sanofi

Active, not recruiting

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Multiple Myeloma | Autologous Stem Cell Transplant | Newly Diagnosed Multiple Myeloma (NDMM)

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Fox Chase Cancer Center
Johnson & Johnson; Mauna Kea Technologies

Active, not recruiting

nCLE For Diagnosis Of Peripheral Lung Nodules By Robotic Navigational Bronchoscopy

Diagnosis of Peripheral Lung Nodules

United States, Netherlands
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
NYU Langone Health
National Cancer Institute (NCI)

Terminated

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Thrombocytopenia | Refractory Multiple Myeloma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)

Monoclonal Gammopathy of Undetermined Significance (MGUS) | Smoldering Multiple Myeloma (SMM)
Oxford University Hospitals NHS Trust
Amgen

Completed

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss (LOOMIS)

Myeloma | Smouldering Myeloma | Monoclonal Gammopathy of Undetermined Significance (MGUS)

United Kingdom
University of Texas Southwestern Medical Center

Withdrawn

Treatment Efficacy of Local Anesthetic/Steroid Mixture Injection for Patients With Odynophonia

Patients With a Diagnosis of Odynophonia
Omnyx, LLC

Unknown

Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens (PrimeDx)

Primary Diagnosis of Surgical Pathology Specimens
Maastricht University Medical Center

Not yet recruiting

Permissive Weight Bearing in Displaced Intra-articular Calcaneal Fractures (PIONEER)

Trauma Injury | Calcaneus Fracture | Displaced Intra-Articular Fracture of Calcaneus (Diagnosis)
Weill Medical College of Cornell University

Unknown

Advanced Imaging Registry for Diagnosing Pancreatico-biliary Disorders

Diagnosis of a Pancreaticobiliary Disorder

United States
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years (LATMM)

Newly Diagnosed Myeloma Patient Above 65 Years Old

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Case Comprehensive Cancer Center

Withdrawn

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Myeloma | Smoldering Myeloma | Monoclonal Gammopathy

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Christoffer Johansen
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Recruiting

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT) (ACT)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma

Denmark
Abramson Cancer Center of the University of Pennsylvania

Completed

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

a Diagnosis of MGUS or SMM by IMWG Criteria

United States
Ohio State University Comprehensive Cancer Center

Completed

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Tel-Aviv Sourasky Medical Center

Completed

Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (KyDaR)

Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Myeloma, Plasma-Cell

Israel
Rennes University Hospital
Intergroupe Francophone du Myelome

Terminated

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. (GENOMGUS)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

France
Zhongnan Hospital

Recruiting

An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

UCB (Cord Blood) Microtransplantation in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Rajavithi Hospital

Completed

Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG

Indication for Modification of Patient Status (Diagnosis)

Thailand
Mayo Clinic

Recruiting

Gynecologic Extramammary Paget's Disease

Extramammary Paget Disease | Paget Disease, Extramammary | Extramammary Paget's Disease | Extramammary Paget's Disease of Vulva (Diagnosis) | Extramammary Paget's Disease of Vagina (Diagnosis) | Extramammary Paget's Disease Vulva Invasive | Extramammary Paget's Disease of Anus (Diagnosis) | Extramammary... and other conditions

United States
Maxx Orthopedics Inc

Recruiting

Evaluation of The Safety And Performance of The Freedom Total Knee® System With The PEEK-OPTIMA Femoral Component

Fractures, Bone | Osteoarthritis, Knee | Rheumatoid Arthritis of Knee | Polyarthritis | Traumatic Arthritis of Knee (Diagnosis)

Belgium
All4Cure
GlaxoSmithKline

Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, Refractory

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Celgene Corporation

Terminated

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Imperial College London
Novartis Pharmaceuticals

Completed

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Chronic Myeloid Leukemia | Newly Diagnosed

United Kingdom
Paola Pisani
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Recruiting

Bone Evaluation by Ultrasound Radiofrequency Echographic Multi Spectrometry (REMS) vs Dual X-ray Absorptiometry (DXA)

Osteoporosis Diagnosis

Italy
Mayo Clinic

Completed

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States

Clinical Trials on Multiple Myeloma of Bone (Diagnosis)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations